Prosecution Insights
Last updated: April 19, 2026
Application No. 17/296,665

HALOGENATED ZINC PHTHALOCYANINE PIGMENT AND PRODUCTION METHOD THEREFOR

Non-Final OA §102§112
Filed
May 25, 2021
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
DIC CORPORATION
OA Round
5 (Non-Final)
74%
Grant Probability
Favorable
5-6
OA Rounds
2y 4m
To Grant
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
818 granted / 1102 resolved
+14.2% vs TC avg
Strong +30% interview lift
Without
With
+30.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
58 currently pending
Career history
1160
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
15.0%
-25.0% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
47.6%
+7.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1102 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/7/2026 has been entered. Status of Claims Claims 1-7, 9-12, and 14 are pending. Claims 1-6 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 7, 9-12, and 14 is contained herein. Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 10/7/2025 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 1/7/2026. New Rejections Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), fourth paragraph: Subject to the [fifth paragraph of 35 U.S.C. 112 (pre-AIA )], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 12 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 12 does not further limit claim 7 with the limitation wherein average number of bromine atoms are “0.1 to 14” since claim 7 states that the average number must be “13 or more”. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claim 12 is rejected under 35 U.S.C. 102(a)(1) as being anticipated over US Patent Application 2017/0009075. US Patent Application 2017/0009075 teaches the claimed chemical formula 1 (halogenated zinc phthalocyanines pigments) wherein X1-X16 may be selected from hydrogen, chloro, or bromo; having an average of 13.97 halogen atoms per molecule, an average of 11.46 being bromine and 2.51 being chlorine (see page 7, [0083], example 1). See other examples (e.g. 2, 3, etc.) as well which meet the claim limitations in reference to halogen atoms. The document illustrates the synthesis of these halogenated phthalocyanine pigments comprising taking a zinc phthalocyanine and subsequent treatment with sulfuryl chloride, aluminum chloride, sodium chloride, and bromine followed by treatment with a base (see example 1). Furthermore note that the specification states that these pigments also require particle diameters of 30 nm or less (see [0022], .01 micrometer being equivalent to 10 nm) as required in the claims. Overall, since the prior art pigment was prepared in an analogous fashion compared to the pigments of the instant application, it would be expected that the prior art compound inherently also possesses the features regarding base adsorption and Al content as recited in claim 7. The claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. In re Best, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977)." Thus, the prior art compound anticipates the instant claims. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 7, 9-12, and 14 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for making and using compositions of a halogenated zinc phthalocyanine pigment having an average of 1.8 Cl atoms and an average of 13.2 Br atoms, does not reasonably provide enablement for making and using the full scope of compositions claimed. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. Pursuant to In re Wands, 858 F.2d 731,737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988), one considers the following factors to determine whether undue experimentation is required: (A) The breadth of the claims; (B) The nature of the invention; (C) The state of the prior art; (D) The level of one of ordinary skill; (E) The level of predictability in the art; (F) The amount of direction provided by the inventor; (G) The existence of working examples; and (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure. Some experimentation is not fatal; the issue is whether the amount of experimentation is "undue"; see In re Vaeck, 20 USPQ2d 1438, 1444. Analysis is described below: (A) Breadth of claims: The claimed compositions may encompass a myriad of phthalocyanine molecules which lead to compounds of a wide variety of structures. The claims cover compounds easily in the thousands given the number of possibilities; thus the claims are very broad. (B) The nature of the invention: (C) (F),(G) State of the Prior Art/ Direction/Examples: Chemistry is unpredictable. See In Re Marzocchi and Horton 169 USPQ at 367 paragraph 3: "Most non-chemists would probably be horrified if they were to learn how many attempted syntheses fail, and how inefficient research chemists are. The ratio of successful to unsuccessful chemical experiments in a normal research laboratory is far below unity, and synthetic research chemists, in the same way as most scientists, spend most of their time working out what went wrong, and why. Despite the many pitfalls lurking in organic synthesis, most organic chemistry textbooks and research articles do give the impression that organic reactions just proceed smoothly and that the total synthesis of complex natural products, for instance, is maybe a labor-intensive but otherwise undemanding task. In fact, most syntheses of structurally complex natural products are the result of several years of hard work by a team of chemists, with almost every step requiring careful optimization. The final synthesis usually looks quite different from that originally planned, because of unexpected difficulties encountered in the initially chosen synthetic sequence. Only the seasoned practitioner who has experienced for himself the many failures and frustrations which the development (sometimes even the repetition) of a synthesis usually implies will be able to appraise such work ......Chemists tend not to publish negative results, because these are, as opposed to positive results, never definite (and far too copious)" Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim pg. IX of Preface. Little guidance or direction is provided by Applicant in reference to making compositions comprising phthalocyanines other than the elected species. Specification offers no teachings or suggestion as to how to make and use these compounds. Also, note MPEP 2164.08(b) which states that claims that read on "... significant numbers of inoperative embodiments would render claims nonenabled when the specification does not clearly identify the operative embodiments and undue experimentation is involved in determining those that are operative.";. As the examiner pointed out; the limited information in the specification provides guidance as to access and subsequently use halogenated zinc phthalocyanine pigments having an average of 1.8 Cl atoms and an average of 13.2 Br atoms employing very specific synthetic steps (see page 34). However no other information is provided besides the aforementioned. Within the specification, “specific operative embodiments or examples of the invention must be set forth. Examples and description should be of sufficient scope as to justify the scope of the claims. Markush claims must be provided with support in the disclosure for each member of the Markush group. Where the constitution and formula of a chemical compound is stated only as a probability or speculation, the disclosure is not sufficient to support claims identifying the compound by such composition or formula.” See MPEP 608.01(p). To complicate the issue; the prior art teaches analogous compositions comprising these phthalocyanines using similar synthetic steps which vary only slightly in amount of reactants used that may afford different average number of halogens present on the molecule (see US Patent Application 2017/0009075, examples 1-3, page 7 and JP 2007-284590, see example 1, [0083]). Thus the art teaches that field is highly unpredictable. (D) Skill of those in the art: The level of skill in the art is high. (E) Level of predictability in the art: (H) The quantity of experimentation needed: Since there are very limited working examples as described above, the amount of experimentation is expected to be high and burdensome. Applicant fails to provide guidance and supporting information for how to make and/or use the thousands of other compounds which are encompassed by the claims, therefore undue experimentation would be expected. Due to the level of unpredictability in the art, the very limited guidance provided, and the lack of working examples, the applicant has shown lack of enablement. MPEP 2164.01(a) states, "A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. In re Wright, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993)." That conclusion is clearly justified here. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN E MCDOWELL/ Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

May 25, 2021
Application Filed
May 25, 2021
Response after Non-Final Action
Jul 02, 2024
Applicant Interview (Telephonic)
Jul 02, 2024
Examiner Interview Summary
Jul 09, 2024
Response Filed
Dec 12, 2024
Non-Final Rejection — §102, §112
Mar 04, 2025
Applicant Interview (Telephonic)
Mar 04, 2025
Examiner Interview Summary
Mar 17, 2025
Response Filed
Apr 28, 2025
Final Rejection — §102, §112
Jun 13, 2025
Request for Continued Examination
Jun 16, 2025
Response after Non-Final Action
Jul 07, 2025
Non-Final Rejection — §102, §112
Aug 20, 2025
Response Filed
Oct 03, 2025
Final Rejection — §102, §112
Oct 27, 2025
Response after Non-Final Action
Jan 07, 2026
Request for Continued Examination
Jan 13, 2026
Response after Non-Final Action
Mar 11, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599615
USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES
2y 5m to grant Granted Apr 14, 2026
Patent 12604600
Organic Electroluminescent Element And Novel Iridium Complex
2y 5m to grant Granted Apr 14, 2026
Patent 12559494
NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
2y 5m to grant Granted Feb 24, 2026
Patent 12552807
PCSK9 INHIBITORS AND METHODS OF USE THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent 12545665
CRYSTAL FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.3%)
2y 4m
Median Time to Grant
High
PTA Risk
Based on 1102 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month